Copaxone (glatiramer acetate, GA), a structurally and compositionally complex polypeptide nonbiological drug, is an effective treatment for multiple sclerosis, with a well-established favorable safety profile. The short antigenic polypeptide sequences comprising therapeutically active epitopes in GA cannot be deciphered with state-of-the-art methods; and GA has no measurable pharmacokinetic profile and no validated pharmacodynamic markers. The study reported herein describes the use of orthogonal standard and high-resolution physicochemical and biological tests to characterize GA and a U.S. Food and Drug Administration-approved generic version of GA, Glatopa (USA-FoGA). While similarities were observed with low-resolution or destructive tests, differences between GA and USA-FoGA were measured with high-resolution methods applied to an intact mixture, including variations in surface charge and a unique, high-molecular-weight, hydrophobic polypeptide population observed only in some USA-FoGA lots. Consistent with published reports that modifications in physicochemical attributes alter immune-related processes, genome-wide expression profiles of ex vivo activated splenocytes from mice immunized with either GA or USA-FoGA showed that 7-11% of modulated genes were differentially expressed and enriched for immune-related pathways. Thus, differences between USA-FoGA and GA may include variations in antigenic epitopes that differentially activate immune responses. We propose that the assays reported herein should be considered during the regulatory assessment process for nonbiological complex drugs such as GA.
Introduction
Copaxone (containing the active ingredient glatiramer acetate, GA), a structurally and compositionally complex polypeptide mixture, is a nonbiological-that is, produced by chemical synthesis-complex drug (NBCD). GA is an antigen-based immunomodulator that elicits a range of cellular and humoral immune responses [1] [2] [3] and is approved for the treatment of relapsing-forms of multiple sclerosis (MS). The mechanism of GA activity is not entirely known, but its therapeutic effects have been linked to activity on multiple components of the immune system over time; most notably, GA appears to modulate the balance between proinflammatory, anti-inflammatory, and regulatory immune cells (T helper type 1 (T H 1), T H 2, and regulatory T cells (T reg cells), respectively). [1] [2] [3] [4] [5] The antigenic peptides in GA have not been identified (and cannot be with current methodologies), although the polypeptide doi: 10.1111/nyas.13547 sequences in the mixture produced under controlled conditions are not entirely random. 6 Upon subcutaneous injection, GA is hydrolyzed locally and has no measurable pharmacokinetic profile. Similarly, no pharmacodynamic markers of GA have been identified or robustly validated. Like other NBCDs, 7 ,8 the quality, antigen homology, and lot-to-lot consistency of GA are the result of a controlled manufacturing process that for GA has remained unchanged in critical parameters affecting composition since the pivotal Copaxone clinical trials in the 1990s.
GA contains polypeptides composed of the four naturally occurring amino acids, that is, l-glutamic acid, l-alanine, l-lysine, and l-tyrosine, at a predefined ratio. GA synthesis involves sequential, tightly controlled steps: first, long chains of amino acids are formed by copolymerization, followed by cleavage into a mixture of shorter polypeptide sequences with an average length of about 60-70 amino acids ranging in molecular size from 5 to 600 nm. The combinatorial complexity of GA sequences reaches up to 10 29 variants in the mixture. 9 Given the high variability of polypeptide sizes and sequences, it is impossible to identify the specific primary sequences of GA epitopes that constitute the therapeutic moieties.
The purpose of conducting the study described herein was to contribute additional data to the research community that would inform the ongoing scientific discussion about how best to establish sameness of GA products comprising a distinct class of NBCDs. As no clinical trial has been conducted comparing GA to USA-FoGA, the specific set of assays that are sufficient to establish that USA-FoGA would have equivalent safety and efficacy to GA in human patients remains an unanswered scientific question.
Recent discussion has highlighted the scientific and regulatory challenges associated with establishing sameness for an NBCD such as GA. 10 In 2016, the U.S. Food and Drug Administration (FDA) issued recommendations (Product-Specific Bioequivalence Recommendations; Draft and Revised Draft Guidances for Industry for Glatiramer Acetate Injection) for the development of generic products of GA based upon establishing sameness of active pharmaceutical ingredient on the grounds of four-part criteria. 11 The first generic followon glatiramer acetate (FoGA) product, USA-FoGA (Momenta/Sandoz, a subsidiary of Novartis), was approved in the United States 12 in accordance with the criteria set forth in an earlier draft of the GA recommendations. 13 Once USA-FoGA received regulatory approval in 2015, it became possible to obtain samples and characterize them using an expanded set of methods, including high-resolution physicochemical methods and gene expression studies with adequate sensitivity in a model system that includes multiple cell types. This expanded set of methods has been used since 2008 by the manufacturer of GA, Teva Pharmaceutical Industries (which employs the authors of the present report) to characterize the chemical composition and biological attributes of FoGAs that have been approved in several countries; the results of those studies have been shared with the scientific community in a series of peer-reviewed publications. 9, [14] [15] [16] [17] [18] The motivation for the present report is to share the data relating to USA-FoGA in order to contribute to the ongoing dialogue in the scientific and medical communities about how best to overcome the challenge of establishing equivalence of follow on versions of NBCDs such as GA. Ten randomly selected lots of GA (expiring February  2016-July 2017: P63148, P63163, P63212, P63213,  P63214, P63227, P63234, P63235, P63240, and  P63246) , and eight lots of USA-FoGA, available for patient use in the U.S. market (expiring September 2016-June 2017: 451253F, 460553F, 470803F, 480853F, 490153F, 531103F, 531203F, and 540253F) were evaluated. Every lot was sampled at least twice for each analysis. All samples were tested under identical experimental conditions, and analyses repeated for robustness.
Methods

Physicochemical tests
Cation exchange chromatography GA and USA-FoGA samples (diluted to 10 mg/mL and 10 L injections) were run on UPLC in a linear gradient from 50% 50 mM H 3 PO 4 mobile phase (solution A) and 50% 50 mM Na 2 HPO 4 solution, to 100% solution A over 20 min on a Propac WCX-10 5 m 150 × 4.0 column (Thermo Scientific), with detection at 210 nm.
Atomic force microscopy
Blinded, independent atomic force microscopy (AFM) analysis was performed by Bar-Ilan University to assess the topography of aggregates in the mixture. The polypeptide mixtures were placed on negatively charged plates and washed as described in Ref. 19 . Images were analyzed and processed using Nanotec WS × M 5.0 (Nanotec Electronica S.L). Images were flattened (i.e., each line of the image was fitted to a polynomial formula, and the polynomial value was then subtracted from the image line).
Two-dimensional multi-angle laser light scattering
Chromatographic separation of GA and USA-FoGA samples (concentration 10 mg/mL and injection volume 100 L) was performed using a Purospher STAR RP-8e 5 m 150 × 4.6 mm column (VWR), with gradient elution from 100% 0.1% TFA in water to 50% 0.1% TFA in acetonitrile over 60 min, at a flow rate of 1 mL/minute. Detector was a MALLS DAWN HELEOS-II (Wyatt Technology).
Viscotek TDAmax
Chromatographic separation of GA and USA-FoGA samples (diluted to 5 mg/mL) was performed at 30°C using a Superose 12 column (GE Healthcare) with pH 2.5 phosphate buffer mobile phase at 0.5 mL/min flow rate. Injection volume was 100 L. OmniSEC software was used.
Ion mobility mass spectrometry
Reverse phase liquid chromatography was applied to six GA and seven USA-FoGA lots with Agilent 6560 Ion Mobility Q-TOF LC/MS. Mass to charge ratios (m/z), drift times in the instrument, and peak intensities were measured and collected for each sample at more than 260,000 data points, followed by a qualitative data analysis. IMMS profiles of all GA lots defined the upper and lower range for the GA. Qualitative assessment compared each USA-FoGA lot profile to the GA range for each data point.
Gene expression analysis
Immunization of mice and preparation of ex vivo spleen cell cultures Mice were obtained and cared for as described in Ref. 9; 8-to 12-week-old female (Balb/c × SJL) F1 mice (Janvier, France) were purchased and kept at 21 ± 3°C with relative humidity 30-70%, and light/dark cycle 12:12 hours. Animals were maintained on a standard rodent pellet diet and sterile filtered tap water available ad libitum. The number of mice was determined necessary to generate a sufficient quantity of splenocytes for the in vitro activation studies described below.
Briefly, to stimulate the induction of GA or USA-FoGA-reactive T cells, 26 mice in each treatment group were injected subcutaneously with 100 L of a 2.5mg/mL drug product solution of either GA (lot P63163) or USA-FoGA (lot 540253F) in phosphate-buffered saline (250 g per mouse). Mice were sacrificed 3 days after immunization, followed by splenocyte preparation and culture.
In vitro activation Splenocytes were treated with mannitol control or activators as described in Ref. 9 , using five different lots of either GA or USA-FoGA. Activator lots were: P63163, P63164, P63165, P63166, P63235 (GA) and 451253F, 480853F, 531103F, 531203F, 540253F (USA-FoGA). All lots were tested in six replicates, each replicate in three wells. The entire study (including both immunization and in vitro activation) was performed twice, resulting in 12 total replicates for each lot. Splenocytes were added to the activator solutions, with each activator sample loaded in a different plate for each of the two immunization conditions. 9 Plates were incubated for 24 h, and cells were collected and lysed. Blinded samples were sent for further processing (EA|Quintiles) as well as genome-wide RNA profiling (Affymetrix Mouse Genome 430_2 chip), which was performed for each of the 12 replicates for each lot.
Data analysis methods for gene expression
Microarray analyses, including normalization, batch correction, and differential expression, utilized methods consistent with the MicroArray Quality Control project.
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Outlier identification and normalization. Outlier samples were identified using the R package ArrayQCMetrics as those failing more than half of the included tests before robust multiarray analysis normalization, resulting in exclusion of one sample. Data were RMA normalized using the Affy R package.
Batch correction. Correction for microarray batch variation was performed using ComBat, 23 as in Ref. 9 . Note that "batch" in this case is unrelated to drug lot. Date of experiment combined with date of microarray run was used as batch, and treatment and immunization were used as covariates. One sample was therefore excluded. Principal component analysis attributed treatment effects (after batch correction) to the first principal component.
Differential expression.
Differentially expressed probesets were identified using linear models for microarray data, 24 a standard R Bioconductor package. Comparison of GA and USA-FoGA was corrected relative to mannitol control via LIMMA. Probesets were filtered by MAS5 calls of presence as described in Ref. 9 and mapped to genes using the annotation available for the Mouse 430 2 chip from Affymetrix. Significance was determined by the false discovery rate (FDR), as implemented in the LIMMA R package. 24 Unless otherwise noted, FDR-adjusted P values reported for genes represent the lowest FDR-adjusted P value for all present probesets for that gene.
Pathway enrichment. Pathway enrichment was conducted using DAVID, 25 as in Ref. 9 , between March and May 2016. Fold change filters were used to obtain probeset lists of appropriate length for pathway analysis. For comparisons between GA and USA-FoGA, up-or down-regulated probesets with FDR-adjusted P < 0.05 and fold changes with absolute value ࣙ1.1 for the mannitol-corrected GA versus USA-FoGA comparison under both immunization conditions were used (i.e., differentially expressed in ex vivo treated splenocytes regardless of whether the mice had been immunized with GA or with USA-FoGA).
qRT-PCR
Nineteen genes were chosen for independent technical assessment by qRT-PCR (EA|Quintiles) using the RNA of GA-immunization samples from the experiment described above. Analysis was conducted as in Ref. 9 , except using as reference the average of four reference transcripts: Actb, Ppib, Tbp, and Rpl13a.
Results
Physicochemical properties
While standard, traditional methods detected no differences between GA and USA-FoGA (data on file, Teva Pharmaceutical Industries, Ltd), highresolution tests identified measureable deviation in physicochemical properties between GA and USA-FoGA, after taking into account GA lot-to-lot variability and analytical test variability. Notably, USA-FoGA samples had significantly higher surface positivity and different sized polypeptide subpopulations compared with GA, with both attributes supported by multiple test platforms. Substantial lot-to-lot variability among USA-FoGA lots was also found.
Cation exchange chromatography (CEX).
CEX is considered the gold-standard for charge-sensitive antibody analysis 26 on the basis of a nondestructive separation of polypeptide mixtures into subgroups by average overall charge. GA (10 lots) and USAFoGA (eight lots) samples consistently comprised three subpopulations represented by distinct peaks on CEX chromatograms: negatively charged, weak positively charged, and strong positively charged polypeptide subpopulations (Fig. 1A) . The distribution of populations in the USA-FoGA lots differed from the three distinct population patterns typical of all GA samples.
A representative range was determined on the basis of the minimum and maximum values of GA lots. All but one of the USA-FoGA lots were either above the GA range (two lots 470803F and 480853F) or below the GA range (five lots 451253F, 490153F, 531103F, 531203F, and 540253F) for the number of negatively charged polypeptides (Fig. 1B) . In all USA-FoGA samples, the number of the weak positively charged polypeptides was lower than the GA range (Fig. 1C) and six of eight USAFoGA lots (451253F, 460553F, 490153F, 531103F, 531203F, and 540253F) contained higher proportions of strongly positively charged polypeptides (Fig. 1D) . Moreover, comparison between the products demonstrated that USA-FoGA exhibited a shift to longer retention times of the strong positively charged polypeptides, indicating qualitative differences between the mixtures (Fig. S1 , online only).
Atomic force microscopy. AFM is a standard technique to determine sample topography, such as aggregation forms. 27 The AFM image allows comparison between aggregation patterns of different positively charged polypeptide constituents adhered to the negatively charged surface. While all samples exhibited linear-folded structures shaped like "strings" in three (i.e., half) of the USA-FoGA samples (lots 451253F, 480853F, and 490153F; Fig. 1E ), the topography was qualitatively different from GA ( Fig. 1F ; representative lots P63212, P63214, and P63213): the density of the structures retained on the negatively charged plate was higher. Given that the overall amino acid distributions of the two glatiramoids are the same, the differential surface charge is likely attributable to differences in the primary structure of polypeptides. The other three USAFoGA lots (531103F, 531203F, and 540253F) tested were found to be qualitatively similar to GA, indicating inter-lot variability of USA-FoGA. Two-dimensional multi-angle laser light scattering (2D-MALLS). MALLS is a technique for determination of the absolute molar mass of particles in solution by light scattering. USA-FoGA lots demonstrate a different and inconsistent pattern when compared with the range composed of 10 GA lots: the molecular mass/hydrophobicity correlations of four USA-FoGA lots were within range (two representative lots 460553F and 451253F are shown in Fig. 2A -B, other two lots are 470803F and 480853F), while the four other USA-FoGA lots fell outside of this range (specifically at RT 32-40 min), exhibiting a unique new subpopulation of higher molecular mass, hydrophobic constituents (two representative lots 531103F and 540253F are shown in Fig. 2C -D, other two lots are 490153F and 531203F). Notably, the four USA-FoGA lots containing this unique peptide subpopulation were distinctly different from other USA-FoGA lots in both CEX (Fig. 2B-D ) and Viscotek TDAmax (described below) analyses.
Viscotek TDAmax gel permeation chromatography. Viscotek TDAmax is a multidetector size-exclusion chromatography analysis system for polymers and macromolecules. 28 The triple detector array of refractive index, viscometer, and light scattering detector provides conformational characterization of polymer constituents, including molecular weight, molecular size, hydrodynamic radius (Rh), intrinsic viscosity (IV; inverse of molecular density), and polydispersity (Pd; a measure of the uniformity of the polymer mixture). Testing of 10 GA and eight USA-FoGA lots showed marked differences in effective size and spatial conformation. USA-FoGA polypeptide chains were folded more loosely in spatial arrangement compared with GA, with statistically significant differences in Rh (mean (SD) 2.793 (0.05) for GA versus 2.93 (0.11) for USA-FoGA, P < 0.0045, Fig. 2E ) and IV (mean (SD) 0.182 (0.01) for GA versus 0.190 (0.01) for USA-FoGA, P < 0.0498). USA-FoGA lots exhibited characteristics of two distinct subgroups, again having a difference in expiration dates, for Rh and IV, while all GA lots exhibited consistent profiles for these attributes; USA-FoGA lots 490153F, 531103F, 531103F, and 540253F had IV and Rh values higher than the maximum IV and Rh values for the GA lots, whereas USA-FoGA lots 451253F, 460553F, 470803F, and 480853F were within GA range of values.
Ion mobility mass spectrometry (IMMS).
IMMS is a two-dimensional technique that allows structural analysis of heterogeneous mixtures by separation of ionized molecules on the basis of molecular size, shape, and mass-to-charge ratio (m/z). 29, 30 It is recommended by the FDA as an analytical tool to evaluate heterogeneity of size, aggregates, and charge hydrophobicity of proteins. 31 Qualitative and quantitative differences in polypeptide composition between USA-FoGA and GA were demonstrated by comparing each of seven USA-FoGA IMMS profiles to the GA (six lots) variability range. A representative scatterplot where results of USA-FoGA lot (531103F) being outside the range of GA are marked with colors (below range marked as red color, above range-blue color) is found in Figure 2F . Frequency distribution of the intensity readings for the USA-FoGA lots indicates that 2.2% of the intensity readings for all USA-FoGA lots fell below the GA range and 3.9% were above the GA range (Table 1) . These observations reflect differences in a combination of attributes, including amino acid sequences, peptide lengths, and relative content of peptides in USAFoGA compared with GA, and are consistent with a recent publication detecting differences in similarly relevant attributes between GA and other FoGAs. 32 Gene expression analyses Because antigen surface charge, amino acid sequence, and size are attributes reported in the literature to affect immune responses, [33] [34] [35] gene expression studies were pursued to investigate the functional relevance of the physicochemical findings. Genome-wide, unbiased transcriptomic analysis of the validated ex vivo activated mouse splenocyte model showed that GA and USA-FoGA similarly modulated thousands of transcripts, including Il10 and Foxp3 (Fig. 3) . Of note, some characteristic modulation was shown with fold-change (FC) <1.5, such as Foxp3 (FC 1.38) , indicating the relevance of subtle FC in this system. However, hundreds of probesets were differentially expressed between GA and USA-FoGA (Table 2) . Overall, 7% of GA-modulated probesets (861 of 12,671) differed significantly between GA and USAFoGA for GA-immunized samples, and similar results were obtained for USA-FoGA-immunized samples (11%, 1615 of 14,517).
To assess the biological relevance of differences between GA and USA-FoGA that were observed consistently under both GA immunization and USA-FoGA immunization, pathway enrichment was performed using top probesets (adj P < 0.05 and |FC| ࣙ 1.1; Table S1 , online only) for the mannitol-corrected GA versus USA-FoGA comparison irrespective of immunization condition (i.e., differentially expressed in ex vivo treated splenocytes regardless of whether the mice had been immunized with GA or with USA-FoGA). Using the widely cited, standard platform DAVID for GO and Kegg pathways, a total of 91 enriched pathways modulated differentially by USA-FoGA compared with GA (72 and 19 pathways among the more highly expressed and the less highly expressed transcripts with USA-FoGA versus GA, respectively). Numerous immune and inflammatory pathways (Table S2 , online only and Fig. 4A ) such as "inflammatory response," "leukocyte mediated immunity," "cytokine-cytokine receptor interaction," and "regulation of type I hypersensitivity" were enriched among probesets upregulated by USA-FoGA relative to GA (adj P < 7.8e-5, 0.003, 2.1e-4, and 0.025, respectively). Enrichment of the "cytokine-cytokine receptor interaction pathway" (Fig. 4B) is notable because it is the most significantly enriched Kegg pathway among top (adj P < 0.05, FC ࣙ 2) probesets upregulated by GA versus mannitol control (adj P < 5.1e-6).
Individual genes important in MS pathogenesis and immune processes were also detected as differentially expressed, such as Mmp9 (adj P < 0.0007), Il6 (adj P < 0.008), Il1b (adj P < 0.04), Ccl2 (adj P < 0.0003), and Csf1r (adj P < 1.0e-5). Levels of genes were increased to a greater extent (e.g., Il6), or decreased to a lesser extent (e.g., Mmp9 and Csf1r), by USA-FoGA relative to GA (termed "upregulated" here). Notably, USA-FoGA upregulated Ccl2 (adj P < 0.012) relative to control, while GA did not (adj P > 0.74). Nineteen genes were subsequently tested by qRT-PCR, confirming microarray observations for each (Fig. 4C and Table 3) .
Lot-to-lot analyses were also performed using the microarray data, comparing individual GA lots to each other, individual USA-FoGA lots to each other, and individual GA lots to individual USAFoGA lots. These analyses showed higher differences between GA and USA-FoGA lots compared with the internal variability between GA lots or between USA-FoGA lots (Table 4) .
Discussion
In this report, comprehensive characterization of Copaxone (GA) and the first FDA-approved FoGA Glatopa (USA-FoGA) found differences in both physicochemical and biological attributes. Lowresolution physicochemical methods detected no differences between GA and USA-FoGA, concordant with Anderson et al. 36 However, USA-FoGA differed from GA in multiple orthogonal, highresolution physicochemical and biological tests. Altered attributes included higher surface charge, which has been previously reported in other contexts to alter immune system processes [33] [34] [35] -a possibility that was confirmed by our gene expression study. Together, the data we provide suggest that compositional differences between USA-FoGA and GA could have functional consequences on inflammatory and immune processes in vivo, and illustrate a challenge for the regulatory assessment process of determining sameness for GA.
CEX and AFM independently demonstrated a higher positive surface charge for USA-FoGA compared with GA. Since the overall amino acid ratio is similar for the two complex compounds, a higher positive surface charge likely reflects a difference in the primary structure of their peptide constituents, such that the positively charged lysine residues appear to be differently/more frequently presented on the surface of USA-FoGA polypeptides. Other physicochemical differences between the two compounds, suggesting differences in the primary structure, included significantly lower spatial organization of USA-FoGA peptides compared with GA, as reflected in the hydrodynamic radius and intrinsic viscosity scores measured using Viscotek analysis. These measures, along with the qualitative differences demonstrated by IMMS, indicate that USA-FoGA has a different composition of polypeptides from that of GA.
Multiple physicochemical tests also highlighted USA-FoGA lot-to-lot compositional inconsistencies that exceeded the microheterogeneity of GA mixtures used here and in prior studies. 6 The unique high-molecular-weight hydrophobic polypeptide population in USA-FoGA detected by 2D-MALLS was found in half of the tested lots, specifically those with later expiration dates. Notably, the same lots showed distinctly different characteristics in CEX and Viscotek analyses. Of note, these same lots also showed the most differences from GA in lot-by-lot differential gene expression comparisons in mouse splenocytes.
The exact composition of GA and USA-FoGA and their lot-to-lot consistency are determined by their manufacturing process. As reported by Momenta in Anderson et al., 36 the Glatopa manufacturing process grossly consists of the same chemical stages as Copaxone-polymerization, depolymerization/partial deprotection, additional depolymerization, and purification. 36 However, the specific parameters used to manufacture USAFoGA remain unknown, and the specific parameters of Teva's manufacturing process for GA remain proprietary. For the latter, multiple conditions in each manufacturing step, as well as purification stages, are tightly controlled to ensure consistent physicochemical composition. Even minimal modifications in conditions (e.g., time or the order of addition of the amino acids or temperature of the reaction) Lot  C63235  C63163  C63164  C63165  C63166  C63235  -0  2  0  1  C63163  -0  0  0  C63164  -0  0  C63165  -0  C63166 -
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can alter composition. 37, 38 The results we describe above, from high-resolution gene expression and other testing, seem to be at odds with some of the statements Anderson et al. make; 36 for example the Glatopa product was manufactured using a process that is equivalent to that of GA . . . . [and] while GA is complex, it is not complicated and is produced by a process that is well documented, well understood and decipherable. Consequently, the impact of process conditions could be elucidated experimentally . . . .
[and] the process conditions need not be identical to produce equivalent material.
Increased positive surface charge shown in the CEX and AFM results has been linked with enhanced immune responses and/or proinflammatory effects. For example, positively charged nanoparticles stimulated the expression of CCL2, a chemoattractant involved in recruitment of immune cells; 35 positive surface charge also led to a fourfold to sixfold higher particle uptake by human dendritic cells in an in vitro model; 33 and positively charged particles also exhibited substantially greater uptake across different cell lines and stem cells, including Jurkat cells, which serve as an in vitro model of immune system T cells. 39 The latter is particularly relevant because imbalances among lineages of T cells are a hallmark of MS, and restoring a normal balance is considered a central outcome of GA therapy.
On the basis of this literature, the physicochemical differences between USA-FoGA and GA were hypothesized to alter USA-FoGA's immune modulation. Genome-wide expression profiling lends further support to this hypothesis, detecting hundreds of genes as differentially modulated by USA-FoGA compared with GA in ex vivo T cell-rich mouse splenocytes, including higher expression of genes and pathways involved in immune responses (e.g., Ccl2, increased relative to control by USA-FoGA but not by GA treatment). While the gene expression studies support the hypothesis that differences in surface charge cause differences in immune modulation, additional experiments would be needed to definitively prove causality.
We wish to highlight that human clinical trials have not been performed with USA-FoGA to assess the safety or efficacy in comparison to GA, and USAFoGA was approved by the FDA 12 on the basis of four criteria intended to establish active ingredient sameness. Hence, the potential clinical differences between GA and any FoGA in both safety and efficacy due to physicochemical and biological differences-some of which are described abovehave yet to be thoroughly explored.
An example of differences found in similar studies and alterations in the efficacy and safety of FoGAs compared with GA is the gene expression research that detected differences between GA and MexicoFoGA, 18 and the results of an analysis of information collected by Teva's patient support program in Mexico. 40 Differences between GA and MexicoFoGA were identified in dozens of immunologically relevant genomic pathways, 18 some of which overlap with the differences reported above. And following the approval of the Mexico-FoGA PROBIOGLAT R (Probiomed), altered efficacy and safety was noted upon switching of patients from GA to MexicoFoGA. 40 These results were subsequently shared with the Mexican authorities. In May 2016, new guidelines were published by the Mexican Department of Health requiring use of high-resolution physicochemical and biological testing for approval of GA generics, specifically citing methods described above (e.g., AFM and IMMS). 41 The findings of differences between USA-FoGA and GA are, we believe, directly relevant to regulatory efforts and support proposed modifications to the FDA's draft guidance on generic versions of GA; 42 specifically, they highlight the need for inclusion of high-resolution characterization tests of the FoGAs marketed to date. Table S1 . Probesets differentially expressed with adj P < 0.05 between USA-FoGA and GA regardless of immunization condition (|FC| ࣙ 1.1). Table S2 . Pathways enriched among top probesets differing in expression with USA-FoGA versus GA under both immunization conditions.
